Adagrasib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase II drugs for Pancreatic Ductal Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Adagrasib LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Adagrasib (Krazati) belongs to the RAS GTPase family, an antineoplastic agent. It is formulated as film coated tablets for oral route of administration. Krazati is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).
Adagrasib is under development for the treatment of solid tumors including advanced colorectal cancer, advanced breast cancer, advanced pancreatic cancer, advanced uterine cancer, gynecological cancer, epithelial ovarian cancer, squamous or non-squamous non-small cell lung cancer, colorectal cancer, breast cancer, glioblastoma multiforme, gastroesophageal (GE) junction carcinomas, ovarian cancer, endometrial cancer, bile duct cancer, metastatic pancreatic cancer and pancreatic ductal adenocarcinoma. It is administered by the oral route as a tablet. The drug candidate acts by targeting KRAS G12C mutations.
Bristol-Myers Squibb overview
Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, medical professionals, hospitals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in Princeton, New Jersey, the US.
For a complete picture of Adagrasib’s drug-specific PTSR and LoA scores, buy the report here.